THERAPY DOSSIER · th-6056d4b6f118

ETS-GS, a water-soluble stable vitamin E derivative

Nutraceutical

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Crush
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 27355403 ↗2016Reported benefit

The Beneficial Effects of ETS-GS, a Novel Vitamin E Derivative, on a Rat Model of Crush Injury.

RatCrushLimb / muscle crushWistarMale

Model: Crush injury induced by compression of bilateral hindlimbs for 6 h followed by release of compression

ETS-GS improved seven-day survival, attenuated the rise in malondialdehyde, interleukin-6 and high mobility group box 1, preserved superoxide dismutase, reduced lung damage and lowered reactive oxygen species generation in lung and muscle.

Extraction: extract · Subtype source: llm · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.

Loading the evidence…